Log in

NASDAQ:AVROAvrobio News Headlines

$17.41
-0.10 (-0.57 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.14
Now: $17.41
$17.56
50-Day Range
$17.32
MA: $20.02
$22.96
52-Week Range
$9.76
Now: $17.41
$29.32
Volume160,200 shs
Average Volume362,033 shs
Market Capitalization$627.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73

Headlines

Avrobio (NASDAQ AVRO) News Headlines

Source:
DateHeadline
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo FinanceAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
finance.yahoo.com - July 9 at 7:43 AM
BRIEF-Avrobio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - ReutersBRIEF-Avrobio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Reuters
www.reuters.com - July 8 at 10:08 AM
Short Interest in Avrobio Inc (NASDAQ:AVRO) Rises By 13.3%Short Interest in Avrobio Inc (NASDAQ:AVRO) Rises By 13.3%
www.americanbankingnews.com - July 7 at 3:36 AM
BRIEF-Avrobio Announces New Patients Dosed In Gaucher Disease And Cystinosis Clinical Trials - ReutersBRIEF-Avrobio Announces New Patients Dosed In Gaucher Disease And Cystinosis Clinical Trials - Reuters
www.reuters.com - July 6 at 12:06 PM
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials - Business WireAVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials - Business Wire
www.businesswire.com - July 6 at 7:06 AM
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical TrialsAVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
finance.yahoo.com - July 6 at 7:06 AM
Notable Two Hundred Day Moving Average Cross - AVRO - NasdaqNotable Two Hundred Day Moving Average Cross - AVRO - Nasdaq
www.nasdaq.com - June 29 at 7:37 PM
AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer - Business WireAVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer - Business Wire
www.businesswire.com - June 29 at 9:34 AM
AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology OfficerAVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer
finance.yahoo.com - June 29 at 9:34 AM
Avrobio Inc (NASDAQ:AVRO) Given Consensus Rating of "Buy" by BrokeragesAvrobio Inc (NASDAQ:AVRO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 28 at 3:16 AM
Hedge Funds Are In Wait and See Mode With Invesco Mortgage Capital Inc (IVR)Hedge Funds Are In Wait and See Mode With Invesco Mortgage Capital Inc (IVR)
finance.yahoo.com - June 27 at 2:12 PM
Avrobio (NASDAQ:AVRO) vs. Editas Medicine (NASDAQ:EDIT) Head to Head AnalysisAvrobio (NASDAQ:AVRO) vs. Editas Medicine (NASDAQ:EDIT) Head to Head Analysis
www.americanbankingnews.com - June 25 at 11:51 AM
Here is What Hedge Funds Think About AVROBIO, Inc. (AVRO)Here is What Hedge Funds Think About AVROBIO, Inc. (AVRO)
finance.yahoo.com - June 24 at 7:08 PM
-$0.77 Earnings Per Share Expected for Avrobio Inc (NASDAQ:AVRO) This Quarter-$0.77 Earnings Per Share Expected for Avrobio Inc (NASDAQ:AVRO) This Quarter
www.americanbankingnews.com - June 20 at 8:23 AM
Avrobio Inc (NASDAQ:AVRO) Short Interest Up 19.3% in JuneAvrobio Inc (NASDAQ:AVRO) Short Interest Up 19.3% in June
www.americanbankingnews.com - June 19 at 4:00 AM
Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones - Business WireMagenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones - Business Wire
www.businesswire.com - June 11 at 9:49 AM
Avrobio Inc. (AVRO) NDR Highlights Possible Accelerated Registration in 2H20 - Mizuho Securities - StreetInsider.comAvrobio Inc. (AVRO) NDR Highlights Possible Accelerated Registration in 2H20 - Mizuho Securities - StreetInsider.com
www.streetinsider.com - June 2 at 8:43 AM
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020 - Business WireAVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020 - Business Wire
www.businesswire.com - May 15 at 12:28 PM
AVROBIO (AVRO) Presents At American Society of Gene & Cell Therapy Meeting - SlideshowAVROBIO (AVRO) Presents At American Society of Gene & Cell Therapy Meeting - Slideshow
seekingalpha.com - May 14 at 4:24 PM
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
finance.yahoo.com - May 14 at 11:24 AM
BRIEF-Avrobio Reports Updated Clinical Data From Investigational Gene Therapy Programs For Fabry Disease And CystinosisBRIEF-Avrobio Reports Updated Clinical Data From Investigational Gene Therapy Programs For Fabry Disease And Cystinosis
www.reuters.com - May 14 at 12:14 AM
Avrobio rallies on gene therapy data in FabryAvrobio rallies on gene therapy data in Fabry
seekingalpha.com - May 13 at 2:13 PM
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and CystinosisAVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
finance.yahoo.com - May 13 at 9:13 AM
Were Not Very Worried About AVROBIOs (NASDAQ:AVRO) Cash Burn RateWe're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
finance.yahoo.com - May 9 at 10:06 AM
We're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn RateWe're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
finance.yahoo.com - May 9 at 10:06 AM
Why Earnings Season Could Be Great for AVROBIO (AVRO)Why Earnings Season Could Be Great for AVROBIO (AVRO)
finance.yahoo.com - May 8 at 2:04 PM
BRIEF-Avrobio Reports 1Q 2020 Financial Results And Provides Business UpdateBRIEF-Avrobio Reports 1Q 2020 Financial Results And Provides Business Update
www.reuters.com - May 7 at 10:39 PM
Avrobio Magenta Collaboration, And Other News: The Good, Bad And Ugly Of BiopharmaAvrobio Magenta Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - May 7 at 5:38 PM
AVROBIO Reports 1Q 2020 Financial Results and Provides Business UpdateAVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
finance.yahoo.com - May 7 at 7:34 AM
AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020
finance.yahoo.com - May 5 at 9:06 AM
AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s ...AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s ...
www.businesswire.com - May 4 at 6:04 PM
BRIEF-Avrobio To Collaborate With Saladax Biomedical On New High-Speed Diagnostic AssayBRIEF-Avrobio To Collaborate With Saladax Biomedical On New High-Speed Diagnostic Assay
www.reuters.com - May 4 at 6:04 PM
AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform GloballyAVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally
finance.yahoo.com - May 4 at 7:12 AM
Fabry Disease Treatment Market Status, Analysis, Reviews and Study Reports 2020 to 2026Fabry Disease Treatment Market Status, Analysis, Reviews and Study Reports 2020 to 2026
www.marketwatch.com - April 29 at 9:44 AM
Is AVROBIO (AVRO) Stock a Solid Choice Right Now?Is AVROBIO (AVRO) Stock a Solid Choice Right Now?
finance.yahoo.com - April 14 at 10:14 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVROSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO
finance.yahoo.com - March 30 at 6:41 PM
AVROBIO Outlines Response to COVID-19 and Current Assessment of Business ImpactAVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact
finance.yahoo.com - March 30 at 6:41 PM
AVROBIO to Participate in Upcoming April Investor ConferencesAVROBIO to Participate in Upcoming April Investor Conferences
finance.yahoo.com - March 26 at 9:30 AM
AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - March 19 at 3:05 PM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 17 at 10:19 PM
AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business UpdateAVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
finance.yahoo.com - March 16 at 7:51 AM
AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for CystinosisAVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
finance.yahoo.com - March 9 at 7:21 AM
Baystate Business: Markets, Politics, Coronavirus (Radio)Baystate Business: Markets, Politics, Coronavirus (Radio)
www.bloomberg.com - February 28 at 7:11 PM
AVROBIO to Present at the Cowen and Company 40th Annual Health Care ConferenceAVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference
finance.yahoo.com - February 24 at 7:46 AM
AVROBIO Announces Closing of Underwritten Public OfferingAVROBIO Announces Closing of Underwritten Public Offering
finance.yahoo.com - February 18 at 5:49 PM
BRIEF-Avrobio Announces Pricing Of Underwritten Public Offering Of $100 Million Of Common StockBRIEF-Avrobio Announces Pricing Of Underwritten Public Offering Of $100 Million Of Common Stock
www.reuters.com - February 13 at 7:17 PM
Avrobio down 11% after pricing equity offeringAvrobio down 11% after pricing equity offering
seekingalpha.com - February 13 at 9:17 AM
17 Stocks Moving In Wednesdays After-Hours Session17 Stocks Moving In Wednesday's After-Hours Session
www.msn.com - February 12 at 11:07 PM
AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common StockAVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock
finance.yahoo.com - February 12 at 11:07 PM
BRIEF-Avrobio Announces Proposed Public Offering Of Common StockBRIEF-Avrobio Announces Proposed Public Offering Of Common Stock
www.reuters.com - February 12 at 6:06 PM
This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.